GlassScriptPhysician profile
Arnold Kirshenbaum
NPI 1831145903
$2,303.40
in general payments reported to CMS, 2019-2025
18 companies · $721 in 2025
The $721 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $47.81 · 2021: $171 · 2022: $540 · 2023: $229 · 2024: $398 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,348.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $604.07 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $461.81 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $321.75 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $209.91 | 2020-2025 | Cuvitru |
| Alk-Abello, INC | $113.41 | 2022 | |
| Biocryst US Sales Co., LLC | $94.88 | 2021-2025 | Orladeyo |
| Csl Behring | $93.04 | 2019-2025 | Andembry, Haegarda |
| Optinose US, INC. | $91.45 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $80.11 | 2019-2025 | |
| Shire North American Group INC | $46.85 | 2019 | |
| Aytu Biopharma, INC. | $36.63 | 2024-2025 | Karbinal |
| Grifols USA, LLC | $36.48 | 2021-2023 | Xembify |
| Blueprint Medicines Corporation | $36.31 | 2025 | Ayvakit |
| Genentech USA, INC. | $31.55 | 2022 | |
| Pfizer INC. | $30.93 | 2020-2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.22 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnold Kirshenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.